To our knowledge, this is the first real‐world study specifically evaluating the impact of smoking history on ICI treatment outcomes in patients with advanced non‐squamous NSCLC, high PD‐L1 expression (≥ 50%), and no EGFR/ALK/ROS1 alterations. The gene discussed is ALK; the disease is non-small cell lung carcinoma.